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Abstract
Problem—Cytomegalovirus (CMV) infection was previously reported in pregnancy 
complications. However, its seroprevalence and associated Toll-like receptor (TLR) expression in 
early onset preeclampsia (EOPE) with Hemolysis, Elevated Liver enzyme and Low Platelets 
syndrome (HELLPs) are unexplored.
Method of study—A case-control study was performed to examine maternal CMV antibodies, 
neutrophil Toll like receptor (TLR)-2 and -4 expression as well as the cytokine profile in EOPE 
with HELLPs (EOPE-HELLPs) (n=10), late onset preeclampsia (LOPE) (n=20), normal 
pregnancy (n=60), and non-pregnancy (n=20) controls.
Results—EOPE-HELLPs had significantly increased CMV IgG sero-positivity, up-regulated 
TLR-2/-4 mRNA expression, elevated serum IL-6 and TNF-α, and reduced IL-10 compared with 
matched normal and non-pregnancy controls. No significant difference was observed between 
LOPE and normal pregnancy controls.
Conclusion—We observed a significant association of CMV infection and innate immune 
response in EOPE-HELLPs. Our data suggest CMV infection may be a risk factor for this 
disorder.
Introduction
Preeclampsia (PE), characterized by hypertension and proteinuria during the second half of 
pregnancy, is a consequence of diverse pathophysiological processes involving impaired 
implantation, endothelial dysfunction and systemic inflammation.1, 2 It is a major cause of 
maternal and fetal mortality and morbidity.3 Preeclampsia is a heterogeneous disorder, and 
has been suggested to subdivide into early onset preeclampsia (EOPE) defined as 
preeclampsia that develops before 34 weeks of gestation, and late onset preeclampsia 
(LOPE) defined as preeclampsia that develops at or after 34 weeks of gestation.4 HELLPs 
(Hemolysis, Elevated Liver enzymes, Low Platelet syndrome), which is regarded as a 
variant of severe pregnancy complication, occurs in 0.5 to 0.9% of all pregnancies and in 
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10–20% of cases with severe preeclampsia.5 Not only is HELLPs a serious obstetric 
complication, but it also places the mother at increased risk for lipoprotein metabolism 
dysfunction later in life, 6 and is associated with severe fetal outcomes, such as prematurity, 
low birth-weight and still birth.7, 8
Human cytomegalovirus (CMV), a ubiquitous intracellular pathogen, is correlated with 
immune-compromised conditions.9, 10 During pregnancy, the maternal immune system 
tends to tolerate fetal derived paternal antigens by suppressing cell-mediated immunity, 
which may induce a state of increased susceptibility to intracellular pathogen reactivation, 
such as CMV.11 Previously, CMV infection was reported in either preeclampsia or HELLPs 
cases,12, 13 and has been reported to initiate Toll-like receptor (TLR) signalling.14
In CMV-seropositive persons, the monocyte appears to be the major cell type harbouring the 
virus in blood, presumably in a latent state.15, 16 However, there are numerous reports that 
the neutrophil is a major reservoir of infectious CMV. 17 In viremic patients, infectious virus 
was more often associated with the neutrophil fraction than the monocyte fraction of 
peripheral blood. The quantity of CMV DNA was significantly greater in poly-
morphonuclear cells than in mononuclear leukocytes. Neutrophils have also been shown to 
stain positively for the CMV structural virion phosphoproteins pp65 (UL83) and pp150 
(UL32).18, 19 Further, evidence suggests that the extent of neutrophil activation correlates 
with the severity of preeclampsia.2021
TLRs comprise the major family of pattern recognition receptors that are involved in innate 
immune response to infectious agents.22, 23 They are expressed in various cell types, 
including circulating immune cells and maternal-fetal interface trophoblasts; their 
expression pattern may vary according to the different stage of pregnancy.23 TLR-2 and 
TLR-4 are expressed on peripheral neutrophils.24 They were known as bacterial sensors, but 
also reported to sense virus infection.25, 26 Although TLR-3 is recognized as a sensor for 
virus expression, it is not expressed on neutrophils.27 A previous study showed that CMV 
activates inflammatory cytokine responses via CD14 and TLR-2.28 CMV also can induce 
TLR-4 signalling and alter downstream cytokine production.25 Polymorphisms in TLR-2 
associate with congenital CMV infection.29 Accumulating evidence also suggest that TLR-2 
and TLR-4 may play important roles in preeclampsia and their expression is unregulated in 
this condition.30
The aim of this study was to examine maternal CMV seroprevalence, neutrophil TLR-2/-4 
expression, and inflammatory cytokines (interleukin [IL]-6, tumour necrosis factor [TNF]-α, 
interferon [IFN]-γ and IL-10) in EOPE with HELLPs (EOPE-HELLPs) and LOPE, 
compared with matched normal pregnancy and non-pregnancy controls.
Methods
Blood was collected from women following informed consent. Ethics approval was granted 
by the University of British Columbia and the Children's and Women's Health Centre of 
British Columbia (C&W).
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HELLPs was defined as hemolysis (defined as serum lactate dehydrogenase (LDH) >600 
U/L and/or haptoglobin ≤0.3 g/L), elevated liver enzymes (serum aspartate aminotransferase 
(AST) >70 U/L or serum alanine aminotransferase (ALT) >70 U/L), and a low platelet count 
(<100×109/L).31 Preeclampsia was diagnosed as hypertension (blood pressure [BP] ≥140/90 
mmHg, taken twice a day more than 4 hours apart after 20 weeks of gestation, and 
proteinuria (≥0.3 g/day, ≥2+ dipstick reading for proteinuria, or ≥30mg protein/mmol 
creatinine)20. BPs were taken in a semi-recumbent position, with a supported arm and 
appropriately-sized cuff, using a manual mercury sphygmomanometer, with Korotkoff V 
used to determine diastolic BP 20.
Study subjects were 30 preeclampsia cases including 10 EOPE-HELLPs (<34 weeks) and 20 
LOPE (≥34 weeks). 60 normal pregnancy controls and 20 non-pregnancy controls were 
matched with cases for maternal age (± 5 years), gestation age (± 2 weeks), and parity (± 1).
Clinical specimen
venous blood was taken antenatally. Serum was prepared by centrifugation and specimens 
were frozen at -80°C for case-control pair analysis. (See method supplement)
Detection anti-CMV IgG, IgM and IgA serology
Enzyme-linked immunosorbent assays (ELISA) were used to detect anti-CMV IgG, IgM 
(Calbiotech, Sprint Valley, CA, USA), and IgA (Diagnostic Automation Inc, CA, USA). 
(See method supplement)
Neutrophil isolation
Neutrophil-enriched cell pellet were isolated and saved for RNA preparation and cDNA 
synthesis (Qiagen RNeasy mini kit and ThermoScript RT-PCR System, Invitrogen, CA, 
USA). (See method supplement)
Relative quantitative SYBR Green real-time polymerase chain reaction (PCR)





TLR-2 and TLR-4 mRNA levels were measured with SYBR Green real-time PCR on a 
Sequence Detection System (ABI Prism 7300, Applied Biosystems), and normalised to an 
endogenous control 18s rRNA. For each clinical sample, the TLR-2/TLR-4 CT value was 
normalized as ΔC = CT (TLR-2/ TLR-4) - CT (18s). This relative expression was measured 
as: ΔΔCT = ΔCT (1) sample-ΔCT(1) calibrator. The value used to plot relative TLR-2/TLR-4 
expression was calculated using the expression 2-ΔΔCT. (See method supplement)
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Neutrophil surface TLR-2 and TLR-4 protein expression was examined with flow cytometry 
(BD FACS Calibur System, Mississauga, ON, Canada). (See method supplement)
Cytokine measurements using multiplex immunoassays
Serum cytokine profile was measured with a multiplexed fluorescent microsphere 
immunoassay by Luminex 100 System (Luminex Corporation, Austin, TX, USA). (See 
method supplement)
Statistics
Data were analysed with Prism 4.0 software (GraphPad, San Diego, CA, USA). Chi-square 
(χ2), Kruskal-Wallis ANOVA (KW), and Mann-Whitney U (MWu) tests were used, as 
appropriate. p <0.05 was considered statistically significant.
Results
Study population characteristics were described in Table 1. Mean maternal age in patients 
with EOPE-HELLPs and the matched controls was 34 and 33 years respectively. EOPE-
HELLPs more likely delivered premature babies and low birth weight babies than matched 
normal pregnancy controls (gestational age 25.9 weeks [24.1, 32.0] versus 37.5 weeks [37, 
39.6], MWu p<0.05; baby birth weight: 1738 gram [395, 3500] versus 3380 gram [3000, 
4615], MWu p<0.05). EOPE-HELLPs had higher CMV IgG seropositive rate (70% versus 
30%, MWu p<0.01) (Table 2) and CMV IgG antibody index level than matched normal 
pregnancy controls (median [range], 1.83 [1.34, 3.99] versus 0.44 [0.11, 2.33], MWu 
p<0.01) (Figure 1). In addition, compared with matched pregnancy controls, EOPE-HELLPs 
was associated with increased TLR-4 (median [interquartile range] (IQR), 1.30 [0.23, 3.42] 
versus 0.51 [0.08, 1.16], MWu p<0.01) and TLR-2 mRNA expression (median IQR, 1.78 
[0.68, 3.38] versus 0.23 [0.02, 0.97], MWu p<0.01). Also, we observed TLR-2 protein 
expression elevated in EOPE-HELLPs compared with normal pregnancies (median IQR, 
2007.5 [900, 4380] versus 845 [200, 2014], MWu p<0.01). Moreover, EOPE-HELLPs had 
elevated serum cytokine IL-6 (median [IQR] 40.5 pg/ml [14.7, 61.2] versus 13.5 pg/ml [5.7, 
35.0], MWu p<0.05), increased TNF-Δ (median [IQR] 5.9 pg/ml [4.4, 12.8] versus 4.5 [2.1, 
9.4], MWu p<0.05), and reduced IL-10 (median [IQR] 16.6 pg/ml [8.5, 30.6] versus 
30.9pg/ml [6.5, 85.2], MWu p<0.05) concentration compared with matched pregnancy 
controls (Figure 2). No significant difference was detected between LOPE and matched 
pregnancy controls (Figure 1, 2 and 3, Table 2). CMV IgG antibody index is correlated with 
inflammatory cytokine IL-6, TNF-α production, TLR-2 and TLR-4 gene expression (See 
data supplement). The association is more likely happened in the same individual (See data 
supplement).
Discussion
This study is the first to show an association of CMV infection, TLR-2/-4 up-regulation, and 
pro-inflammatory phenotype in EOPE-HELLPs, but not in LOPE, compared with matched 
pregnancy controls. A previous study reported the odds ratio for perinatal death and severe 
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neonatal morbidity was significantly increased in EOPE compared with LOPE.32 We 
observed EOPE cases more frequently delivered premature babies, and more likely 
developed HELLPs, which was similar to published findings.30,33 EOPE and LOPE may 
share some etiologic features, but differ with regard to several risk factors, and lead to 
different outcomes.32 The two preeclampsia types should therefore be treated as distinct 
entities from an etiologic and prognostic standpoint.32
In the present study, we examined three classes of CMV-specific serum antibodies IgG, IgM 
and IgA, which were measured among EOPE with HELLP syndrome, LOPE, and matched 
normal pregnancy controls. IgG indicates previous infection; anti-CMV IgM suggests acute 
or primary CMV infection; and anti-CMV IgA is associated with primary, chronic, or 
recurrent infections 34, but it is not a specific indicator for CMV infection. In chronic or 
recurrent infection, detectable IgM is uncommon, while IgG levels may rise quickly 34. 
Previously, we have observed increased anti-CMV IgG antibody level in women who later 
developed EOPE 35. To confirm CMV primary infection or reactivation, CMV avidity 
testing should be applied, since it is a useful method to distinguish CMV primary infection 
from non-primary infection and reactivation.36
Several mechanisms may explain the relation between CMV infection and EOPE-HELLPs. 
CMV infection has direct effects on the arterial wall, including endothelial-platelet 
dysfunction 37 and acute atherosis, which can result in relative uteroplacental ischemia, a 
key pathogenic feature in EOPE.38 CMV infection also has indirect effects, via immune 
CD14, TLR-2 and TLR-4, to induce pro-inflammatory cytokines, as an initiator of placental, 
fetal injury and liver dysfunction.26, 39 Moreover, increasing evidence suggests that up-
regulated TLR expression plays an important role in the apoptosis in first trimester 
trophoblast cells; 40 and elevated circulating IL-6 and TNF-α contribute to endothelial 
dysfunction, which may link with the pathogenesis of EOPE and HELLPs 33, 41,42
The primary limitation of this work was the relatively small sample size. Additionally, it 
was designed for primiparous subjects, and may not be extrapolated to multiparous women. 
Given the finding concerning CMV infection in the present study, to attain sufficient 
statistical power, our data needs to be confirmed in a larger obstetric population followed 
longitudinally.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CMV Antibody Index in cases and controls.
Note: CMV IgG, IgM and IgA antibody indices were measured with ELISA. Data were 
shown as individual points and bars with the median. EOPE: early onset preeclampsia. 
HELLPs: H=hemolysis, EL= elevated liver enzymes, LP=low platelet, s=syndrome; 
EOPEHELLPs: early onset preeclampsia with HELLP syndrome. LOPE: later onset 
preeclampsia. Ctrl, matched normal pregnancy control; Data were first compared across all 
columns to calculate Kruskal-Wallis (KW) ANOVA. Between-column comparisons were 
performed to compare EOPE-HELLPs versus Ctrl (EOPE-HELLPs), and LOPE versus Ctrl 
(LOPE) by Mann-Whitney U (MWU) test. ** indicates p <0.01.
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Inflammatory cytokine profile in cases and controls.
Note: Inflammatory cytokine IL-6, TNF-α, IL-10, IL-2 and IFN-gamma were measured 
with ELISA. Data was expressed as median [range]. Ctrl, matched normal pregnancy 
control; EOPE: early onset preeclampsia. HELLPs: H=hemolysis, EL= elevated liver 
enzymes, LP=low platelet, s=syndrome; EOPE-HELLPs: early onset preeclampsia with 
HELLP syndrome. LOPE: later onset preeclampsia. Data were first compared across all 
columns to calculate Kruskal-Wallis (KW) ANOVA. Between-column comparisons were 
performed to compare EOPE-HELLPs versus Ctrl (EOPE-HELLPs); LOPE versus Ctrl 
(LOPE) by using Mann-Whitney U (MWu) test. * indicates p <0.05; ** indicates p <0.01.
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TLR-4 and TLR-2 mRNA and protein expression in cases and controls.
Note: The data were shown as individual points and bars with the median. Ctrl, matched 
normal pregnancy control; EOPE: early onset preeclampsia. HELLPs: H=hemolysis, EL= 
elevated liver enzymes, LP=low platelet, s=syndrome; EOPE-HELLPs: early onset 
preeclampsia with HELLP syndrome. LOPE: later onset preeclampsia. Data were first 
compared across all columns to calculate Kruskal-Wallis (KW) ANOVA. Between-column 
comparisons were performed to compare EOPE-HELLPs versus Ctrl (EOPE-HELLPs), and 
LOPE versus Ctrl (LOPE) by Mann-Whitney U (MWU) test. * indicates p <0.05; ** 
indicates p <0.01.
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